News & Updates

In patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD), treatment with canagliflozin safely decreases the risk of developing end-stage renal disease, reports a new Japan study.

Young patients with type 1 diabetes mellitus (T1DM) find the noninvasive nature of ketone breath sensor devices attractive, especially as compared with blood testing, according to a recent study. Still, concerns about such devices remain, including their ease of use, accuracy, and affordability.

Obesity and metabolic comorbidities appear to be common among patients with large hepatocellular adenomas (HCAs) and adenomatosis, reports a study.

In children with newly diagnosed inflammatory bowel disease (IBD), overweight and obese status are not associated with worse disease activity at 1 year after diagnosis compared with normal weight, results of a study have shown.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are superior to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing renal outcomes among patients with type 2 diabetes (T2D) in Hong Kong, a real-world population-based study by the University of Hong Kong has shown.

The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.